Navigation Links
ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
Date:10/22/2007

WASHINGTON, DC OCTOBER 22, 2007 Late-breaking results from the ENDEAVOR IV trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting stent met the trials primary endpoint, demonstrating a similar overall safety profile (equivalent rates of death, heart attack, and repeat procedures) to the Taxus paclitaxel-eluting stent at 1 year.

In addition, the Endeavor stent showed a lower rate of less-severe (non-Q-wave) heart attacks at 30 days, but a higher rate of angiographic late loss (artery re-narrowing) at eight months compared to the Taxus stent.

The primary endpoint of the trial, non-inferiority as measured by target vessel failure (TVF) between the two stents, was met, said Martin B. Leon, MD, Founder and Chairman Emeritus, CRF and Professor of Medicine at Columbia University Medical Center. TVF occurred in 6.6 percent of patients receiving the Endeavor stent and 7.2 percent of patients receiving the Taxus stent, a difference that was not statistically significant. The Endeavor stent also demonstrated equivalence to Taxus in several long term measures.

At 12 months, the difference between the rates of target lesion revascularization with the Endeavor (4.5 percent) and Taxus (3.2 percent) stents was not statistically significant. Likewise, target vessel revascularization rates at 12 months were also similar (6.3 percent with Endeavor vs. 6.7 percent with Taxus).

Interestingly, at 30 days, rates of less-severe heart attacks were 0.5 percent with Endeavor compared with 2.2 percent with Taxus, a statistically significant difference. Late loss at eight months, meanwhile, was significantly greater with Endeavor (0.67 mm) compared with Taxus (0.42 mm).

Importantly, in the diabetic subset of 477 patients, Endeavor had similar efficacy compared with Taxus including target lesion revascularization and in-segment restenosis.

The Endeavor IV trial included 1,548 patients at 80 locations and was randomized to treatment with either the Endeavor or Taxus stent.


'/>"/>

Contact: David Harrison
david@harrisoncommunications.net
410-804-1728
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. ENDEAVOR III Trial Reports Key Findings on New-generation Stent
2. Human Genome Project Achieves Technological Triumph
3. A Village in Madhya Pradesh Achieves Total Sanitation
4. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
5. Is caries in primary and permanent tooth related?
6. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
7. Shortage Of Funds In Primary Care Trust In UK
8. What Will Primary Care Look Like In England by 2015?
9. Primary Health Care MoU Signed on the Sidelines of the PBD
10. Primary Care centers to provide out patient treatment
11. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... which come courtesy of leaders in the nursing and health care industry. It also ... and associations—namely Abilene Christian University. , As the nursing industry is coming out ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its ... partner for the Tamika Catchings Legacy Tour that will commemorate the Indiana ... hardwood basketball surfaces in all forms and levels of the game, Connor Sports has ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May ... QGEN ; Frankfurt Prime Standard: QIA) today announced that ... with Therawis Diagnostics GmbH to develop and commercialize predictive assays ... market PITX2 as a marker to predict effectiveness of anthracycline ... "We are pleased to partner with Therawis, which ...
(Date:5/25/2016)... -- According to Kalorama Information, the world market for ... these are challenging times in the market, there ... companies that remain optimistic and seek innovation.  Toward ... medical device companies spend a higher percentage of ... do companies in other industries.  Also, in addition ...
Breaking Medicine Technology: